Last reviewed · How we verify
Struvite Renal Calculi — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Renacidin | MAGNESIUM CARBONATE | United Guardian | Vitamin C [EPC] | 1990-01-01 | ||
| Lithostat | ACETOHYDROXAMIC ACID | Mission Pharma | Urease Inhibitor [EPC] | Carbonic anhydrase 2 | 1983-01-01 | |
| Renacidin | CITRIC ACID | Baxter | Anti-coagulant | 1982-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Baxter · 1 drug in Struvite Renal Calculi
- Mission Pharma · 1 drug in Struvite Renal Calculi
- United Guardian · 1 drug in Struvite Renal Calculi
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Struvite Renal Calculi:
- Struvite Renal Calculi treatment updates — RSS
- Struvite Renal Calculi treatment updates — Atom
- Struvite Renal Calculi treatment updates — JSON
Cite this brief
Drug Landscape (2026). Struvite Renal Calculi — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/struvite-renal-calculi. Accessed 2026-06-10.
Related
- Struvite Renal Calculi full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing